Accelmed Partners Amends Strata Skin Sciences 13D Filing

TL;DR

Accelmed Partners updated their Strata Skin Sciences 13D filing, adding more group members. No new shares bought/sold.

AI Summary

Accelmed Partners, L.P. and its affiliates filed an amendment to their Schedule 13D on July 18, 2024, regarding their beneficial ownership of Strata Skin Sciences, Inc. The filing indicates a change in the group members, with Accelmed Growth Partners (AGP) Ltd., Accelmed Growth Partners Management Ltd., and Accelmed Partners (GP), L.P. now listed as group members alongside Accelmed Partners (GP), L.P. and Uri Geiger. No specific new shareholdings or dollar amounts were detailed in this amendment.

Why It Matters

This amendment signals a potential shift in the control or strategic interests of Accelmed Partners in Strata Skin Sciences, which could impact the company's future direction and stock performance.

Risk Assessment

Risk Level: medium — Amendments to 13D filings often precede significant corporate actions or changes in control, introducing uncertainty for investors.

Key Players & Entities

• Accelmed Partners, L.P. (company) — Filing entity
• Strata Skin Sciences, Inc. (company) — Subject company
• Accelmed Growth Partners (AGP) Ltd. (company) — Group member
• Accelmed Growth Partners Management Ltd. (company) — Group member
• Accelmed Partners (GP), L.P. (company) — Group member
• Uri Geiger (person) — Group member

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class o
• $723,999 — gregate purchase price of approximately $723,999. Item 5. Interest in Securities of the

Filing Documents

• ea0209650-13da1accel_strata.htm (SC 13D/A) — 88KB
• 0001213900-24-062681.txt ( ) — 90KB

Identity and Background

Item 2. Identity and Background. Items 2 of the Initial 13D is hereby amended and restated as follows: This statement is being filed by: (a)Accelmed Partners, L.P. (the “Fund”); (b)Accelmed Partners (GP), L.P. (the “GP”); (c)Accelmed Growth Partners (AGP) Ltd. (the “GPGP”); (d)Accelmed Growth Partners Management Ltd. (the “Management Company”); and (e)Uri Geiger, the controlling member and managing partner of the GPGP and the controlling shareholder and managing partner of the Management Company. The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.” The Reporting Persons have entered into a Joint Filing Agreement, a copy of which was filed with the Initial 13D. The address of the principal business office of the Reporting Persons is Accelmed Partners, L.P., 848 Brickell Ave., 9th Floor, Miami, FL 33131. The principal business of the Fund is to invest in medical device companies. The principal business of the GP is to act as the sole general partner of the Fund. The principal business of the GPGP is to act as the sole general partner of the GP. The principal business of the Management Company is to manage the Fund. The principal business of Uri Geiger is to manage the Fund and affiliated entities. During the five years prior to the date hereof, none of the Reporting Persons have been convicted in a criminal proceeding or have been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Fund and the GP are Cayman Island exempted limited partnerships. The GPGP and the Management Company are Cayman Island private limited companies. Uri Geiger is an Israeli citizen. CUSIP: 86272A 305 Page: Page 8 of 8

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration

is hereby amended by adding the following

Item 3 is hereby amended by adding the following to the end of Item 3 of the Initial 13D. On July 15, 2024, the Reporting Persons purchased an additional 230,573 shares of Common Stock in a block trade through the agent of the Company’s Equity Distribution Agreement. This acquisition was funded with the working capital funds of Accelmed Partners, L.P. for an aggregate purchase price of approximately $723,999.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer Items 5(a), (b) and (c) of the Initial 13D are hereby amended and restated as follows: (a) See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of shares of Common Stock and percentages beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 35,060,920 shares of Common Stock outstanding as of May 13, 2024, as disclosed in the company’s Form 10-Q filed May 15, 2024, as adjusted for the 1-for-10 reverse stock split effected on June 6, 2024, as further adjusted for the issuance of the 230,573 shares of Common Stock purchased by the Reporting Persons as set forth in Item 3 above. (b) See rows (7) through (10) of the cover pages to this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. (c) The following table sets forth all transactions with respect to shares of the Common Stock effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, by any of the Reporting Persons during the past sixty (60) days. Name of Reporting Person Date of Transaction Type of Transaction Number of Shares of Common Stock Price per Share of Common Stock Accelmed Partners, L.P. 7/15/2024 Purchase 230,573 $ 3.14 After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: July 18, 2024 ACCELMED PARTNERS, L.P. By Accelmed Partners (GP), L.P., its general partner By Accelmed Growth Partners (AGP) Ltd., its general partner By: /s/ Uri Geiger Name: Uri Geiger Title: Managing Partner ACCELMED PARTNERS (GP), L.P. By Accelmed Growth Partners (AGP) Ltd., its general partner By: /s/ Uri Geiger Name: Uri Geiger Title: Managing Partner ACC

View Full Filing

View this SC 13D/A filing on SEC EDGAR